News: Palatin Technologie Inc (PTN.A)
0.27USD
1:09pm EST
$0.02 (+8.00%)
$0.25
$0.24
$0.30
$0.24
99,100
388,551
$0.47
$0.06
Fri, Nov 9 2007
Palatin Technologies Q1 results
PALATIN TECHNOLOGIES INC : * First quarter per share loss $0.00 * First quarter revenue $9 million versus $4.9 million * Says decrease in first quarter loss due to recognition of deferred license revenue * Reuters Estimates first quarter earnings per share view $-0.10
Palatin cuts 30 pct of its workforce, to take related charge
Sept 26 (Reuters) - Palatin Technologies Inc said it will reduce its workforce by 30 percent, a month after U.S. health regulators raised concerns on the efficacy of the company's drug to treat male erectile dysfunction.
TABLE-Palatin Technologies Q4 loss narrows
PALATIN TECHNOLOGIES INC (In $) Latest Yr ago qtr Loss/shr (diluted) 0.07 0.11 Net loss (million) 6.1 7.9 Total revenue (million) 2.6 5.0 Reuters Estimates: Loss/shr $0.09, revenue $6.5 million
Palatin refutes Competitive Tech's statement on license deal
Sept 12 (Reuters) - Palatin Technologies Inc said Competitive Technologies Inc's statement on Tuesday relating to a material breach and termination of a license agreement was "false and misleading."
Palatin says King Pharma ends drug agreement on FDA concern
Sept 10 (Reuters) - Palatin Technologies Inc said King Pharmaceuticals Inc ended its collaborative development agreement on bremelanotide used in the treatment of male erectile dysfunction and female sexual dysfunction.
Palatin, King Pharma delay late-stage trial plans for drug
Aug 30 (Reuters) - Palatin Technologies Inc and King Pharmaceuticals Inc said they delayed plans for the late-stage clinical trials of bremelanotide used in the treatment of male erectile dysfunction, after U.S. health regulators raised safety concerns.
- Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
- Palatin Technologies, Inc. F4Q09 (Qtr End 06/30/09) Earnings Call Transcript
- Closing Update for Wednesday, August 12: The Fed's Relative Optimism Is Catching
- Cash for Cardiovascular: Who Might Be Next?
- Palatin Technologies, Inc. F2Q09 (Qtr End 12/31/08) Earnings Call Transcript
- Palatin Technologies, Inc. F4Q08 (Qtr End 06/30/08) Call Transcript
Press Releases
- Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate
- Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on November 16, 2009
- Palatin Technologies, Inc. To Report Fiscal Year 2010 First Quarter Results; Teleconference and Webcast to be held on November 16, 2009
- Palatin Technologies to Present at 8th Annual BIO Investor Forum
- Palatin Technologies to Receive $5 Million from AstraZeneca
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
